SILVER SPRING, Md. – The XSTAT P15 applicator, an advanced hemorrhage control device for narrow-entrance wounds, was awarded funding through the Accelerate the Procurement and Fielding of Innovative Technologies (APFIT) program on July 14, 2026.
The FDA-cleared applicator, designed through joint efforts by Naval Medical Research Command (NMRC) in partnership with RevMedX, is designed to reduce casualties in deployed and combat environments by treating life-threatening bleeding wounds.
APFIT, a competitive DoW program, provides funding to small, U.S.-based vendors, with the goal of closing the gap between finished products and the hands of service members by transitioning new technologies into operational environments.
“Securing...
SINAI, Egypt (July 13, 2026) Capt. Wilbert Paige, preventive medicine officer for Multinational Force and Observers, and Alia Zayed, entomology advisor for U.S. Naval Medical Research Unit (NAMRU) EURAFCENT, inspect a concealed area that may serve as a mosquito breeding site during a vector surveillance assessment. Surveillance activities help identify environmental conditions that may contribute to vector-borne disease risks affecting deployed personnel. NAMRU EURAFCENT, part of Navy Medicine Research & Development, conducts research, surveillance and studies of vaccines, therapeutic agents, diagnostic assays and vector control measures in the EUCOM, AFRICOM and CENTCOM Areas of Responsibility to better prevent and treat infectious diseases in support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality. (U.S. Navy Courtesy Photo/Released)
